Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2004-02-09
2010-11-09
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S141100, C514S002600
Reexamination Certificate
active
07829091
ABSTRACT:
The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
REFERENCES:
patent: 4543439 (1985-09-01), Frackelton, Jr. et al.
patent: 4652639 (1987-03-01), Stabinsky
patent: 4933294 (1990-06-01), Waterfield et al.
patent: 5183884 (1993-02-01), Kraus et al.
patent: 5185438 (1993-02-01), Lemischka
patent: 5198359 (1993-03-01), Taniguchi et al.
patent: 5231001 (1993-07-01), Kaplan et al.
patent: 5256766 (1993-10-01), Coughlin
patent: 5270458 (1993-12-01), Lemischka
patent: 5283354 (1994-02-01), Lemischka
patent: 5367057 (1994-11-01), Lemischka
patent: 5635177 (1997-06-01), Bennett et al.
patent: 5643759 (1997-07-01), Pfreundschuh
patent: 5693762 (1997-12-01), Queen et al.
patent: 5700822 (1997-12-01), Hirth et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5747651 (1998-05-01), Lemischka
patent: 5750078 (1998-05-01), Shitara et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5763733 (1998-06-01), Whitlow et al.
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5798097 (1998-08-01), McKenzie et al.
patent: 5807548 (1998-09-01), Shitara et al.
patent: 5952199 (1999-09-01), Davis-Smyth et al.
patent: 6011003 (2000-01-01), Charnock-Jones et al.
patent: 6331302 (2001-12-01), Bennett et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6824777 (2004-11-01), Alitalo et al.
patent: 0 325 224 (1989-07-01), None
patent: WO 90/14425 (1990-11-01), None
patent: WO 92/14748 (1992-03-01), None
patent: WO 92/13867 (1992-08-01), None
patent: WO 93/14124 (1993-07-01), None
patent: WO 93/15201 (1993-08-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 95/24473 (1995-09-01), None
patent: WO 95/33772 (1995-12-01), None
patent: WO 96/39515 (1996-12-01), None
patent: WO 97/05250 (1997-02-01), None
patent: WO 97/09427 (1997-03-01), None
patent: WO 98/07832 (1998-02-01), None
patent: WO 98/33917 (1998-08-01), None
patent: WO 99/33485 (1999-07-01), None
Alitalo et al., Lymphangiogenesis in development and human disease, 2005, Nature, vol. 438, pp. 946-953.
Tammela et al., The biology of vascular endothelial growth factors, 2005, Cardiovascular Research, vol. 65, pp. 550-563.
Ferrara et al., Clinical applications of angiogenic growth factors and their inhibitors, 1999, vol. 5, pp. 1359-1364.
Karpanen et al., Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation, 2006, The American Journa of Pathology, vol. 169, No. 2, pp. 708-718).
Achen, M.G. et al., “Vascular endothelial growth factor D (VEGF-F) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4),”Proc. Natl. Acad. Sci., USA, 95(2):548-553 (Jan. 1998).
Achen, M.G. et al., “Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3,”Eur. J. Biochem, 267(9):2505-15 (May 2000).
Andersson et al., “Structural and Functional Markers During Induced Differentiation in Human Leukemia Cell Lines,”InR. F. Revoltella (ed.),Expression of Differentiated Functions in Cancer Cells. 239-245, Raven Press, New York (1982).
Andre, T., et al., “Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FL the neoplastic progression of human colonic mucosa,”Int. J. Cancer, 86(2):174-81 (Apr. 15, 2000).
Akagi, K., et al., “Vascular endothelial growth factor-C (VEGF-C) expression in colorectal cancer tissues,”Br. J. Cancer, 83(7):887-91 (Oct. 2000).
Aprelikova et al., “FLT4, A Novel Class III Receptor Tyrosine Kinase in Chromosome 5q33-qter,”Cancer Research, 52(3):746-748 (Feb. 1, 1992).
Aujame, L. et al., “High affinity human antibodies by phage display,”Human Antibodies, 8(4):155-168 (1997).
Beckstead, J.H. et al., “Evidence for the Origin of Kaposi's Sarcoma From Lymphatic Endothelium,”Am. J. Pathol., 119(2):294-300 (May 1985).
Beers and Berkow eds. The Merck Manual of Diagnosis and Thereapy, Seventeenth Edition, pp. 986-995, Merck & Co., Inc. Whitehouse Station, N.J., 1999.
Berridge et al., “Cell-Lineage Antigens of the Stem Cell-Megakaryocyte-Platelet Linkage are Associated with the Platelet IIb-IIa Glycoprotein Complex,”Blood, 66(1):76-85 (Jul. 1985).
Bolen, J.B., “Nonreceptor Tyrosine Protein Kinases,”Oncogene, 8:2025-2031 (1993).
Bolhuis, R.L. et al., “T cell targeting in cancer therapy,”Cancer Immunology Immunotherapy, 34(1):1-8 (1991).
Borg et al., “Biochemical Characterization of Two Isoforms of FLT4, a VEGF Receptor-Related Tyrosin Kinase,”Oncogene, 10:973-984 (1995).
Brown, L.F. et al., “Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer,”Human Pathology, 26(1):86-91 (Jan. 1995).
Brüggemann, M. et al., “Production of human antibody repertoires in transgenic mice,”Curr. Opin. Biotechnol., 8:455-458 (1997).
Brüggemann, M. et al., “Strategies for expressing human antibody repertoires in transgenic mice,”Immunol. Today, 17(8):391-397 (Aug. 1996).
Bunone, G., et al., “Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features,”Am. J. Pathol, 155(6):1967-76 (Dec. 1999).
Cantley et al., “Oncogenes and Signal Transduction,”Cell, 64:281-302 (Jan. 25, 1991).
Cao, Y., et al., “Vascular endothelial growth factor C induces angiogenesis in vivo,”Proc. Natl. Acad. Sci. USA, 95:14389-94 (Nov. 1998).
Carter, P. et al., “Toward the Production of Bispecific Antibody Fragments for Clinical Applications,”Journal of Hematotherapy, 4:463-470 (1995).
Catoretti et al., “Monoclonal Antibodies Against-Recombinant Parts of the Ki-67 Antigen (MIB 1 and MIB 3) Detect Proliferating Cells in Microwave-Processed Formalin-Fixed Paraffin Section,”J. of Pathol., 168:357-363 (1992).
Cheng & Flanagan, “Identification and Cloning of ELF-1, a Developmentally Expressed Ligand for the Mek4 and Sek Receptor Tyrosine Kinases,”Cell, 79:157-168 (Oct. 7, 1994).
Cole et al., “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,”Monoclonal Antibodies and Cancer Therapy, Alan R Liss, Inc., pp. 77-96 (1985).
Collins et al., “Continuous Growth and Differentiation of Human Myeloid Leukaemic Cells in Suspension Culture,”Nature, 270:347-349 (1977).
De Gast, G.C. et al., “Clinical perspectives of bispecific antibodies in cancer,”Cancer Immunol Immunother, 45:121-123 (1997).
De Vries et al., “Thefms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor,”Science, 255:989-991 (Feb. 21, 1992).
De Waal, R. et al., “Technical Advance: Lack of Lymphangiogenesis in Human Primary Cutaneous Melanoma,”American Journal of Pathology, 150(6):1951-1957 (Jun. 1997).
Devereux et al., “A Comprehensive Set of Sequence Analysis Programs for the VAX,”Nucleic Acids Res., 12(1):387-395 (1984).
Dias, et al., “Vascular endothelial growth factor (VEGF)-C signaling through FLt-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy,”Blood, 99:2179-2184 (2002).
Dictor, M. et al., “Lymphaticovenous Differentiation in Kaposi's Sarcoma: Cellular Phenotypes by Stage,”American Journal of Pathology, 130(2):411-417 (Feb. 1988).
Edgell et al., “Permanent Cell Line Expressing Human Factor VIII-Related Antigen Established by Hybridization,”Proc. Nat'l. Acad. Sci. USA, 50:3734-3737 (Jun. 1983).
Eggert, A., et al., “High-Level Expression of Angiogenic Factors Is Associated with Advanced Tumor Stage in Human Neuroblastomas,”Clin. Cancer Res., 6(5):1900-8 (May 2000).
Eichmann et al., “Molecular cloning of Quek 1 and 2, two quail vascu
Dang Ian
Landsman Robert
Marshall & Gerstein & Borun LLP
Vegenics Limited
LandOfFree
Therapy targeting FLT4 (VEGER-3) expressed in blood vessels does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapy targeting FLT4 (VEGER-3) expressed in blood vessels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy targeting FLT4 (VEGER-3) expressed in blood vessels will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173612